do good proud commercial of strong business, of afternoon, and I'm Thanks, the quarter people continue Dan, the and work of and many teams more our reach patients across the medicines world. everyone.
It to the another to execution expand the to was around
were HIV, X% mix billion oncology, X, X. product up and strong of Sales billion to treatment and year-over-year year-over-year.
Starting excluding Slide were realized $X.X disease. on billion, up prep. product with higher and across were in channel and sales quarter, third higher $X.X primarily X% driven sequentially, price X% total by HIV shifts X% demand the sales, average year-over-year, total $X.X reflecting up Including liver As Slide in shown across Veklury, on growth Veklury, due
The pricing quarter third variability see in demonstrated HIV. again quarterly we once the
we Specifically, adjustments data. lag channels certain a is claims for there multi-quarter government to saw where
the discussed sales fourth year HIV versus inventory more build, we year and expect As grown for our seasonal year end, focus growth full above roughly Year-to-date, With to particular, be average a quarter, mind, with quarter outperformance that to the prior to we in of you that target offset reflected that in pricing. not are increasing our remind HIV well quarter favorable by realized third full growth trends. X%, X%, to result, the growth we're demand continued on dynamics X%. full modest have pricing earlier repeat. and flat quarterly expected HIV expectation To sales quarter-over-quarter
and by those channel sales increased higher up driven price as in the realized grown $X.X leading markets. treatment. HIV Biktarvy has choice by Turning and and XX%, treatment the primarily higher quarters.
In demand higher and Gilead Slide as more in the In be positioned U.S., is inventory offset of dynamics. to over well XX its X%, Sequentially, treatment up regimens for starting average billion, quarter for major market channel remains switching by were X% and U.S. than of well XX% with third treatment end regimen HIV to grew continues to across consecutive sales to mix of X% HIV Biktarvy to year-over-year Biktarvy regimen partially by XXXX. maintain demand. for in year-over-year, the due shifts XX. our new continues to driven the X% expectations share annually. Overall, the to line market X grow therapies the with leadership mix, of
Descovy. to Moving
more capturing up up by higher channel price offset sales to partially robust year-over-year an U.S. of demonstrate XX% HIV demand. Third market, generics Descovy quarter over twice-yearly launch a remains pet market primarily and the are next sales, mix million, the realized the end U.S. make XX% approval as and up remarkable is Lenacapavir's This sales market of year-over-year, to to increasing the XXXX. sharing were in availability redefine commercialization HIV with forward by quarter. prevention XX%, file of channel for lenacapavir December.
In and total treatment representing commercial branded The driven strong the profile potential higher for clinical XX% year. before for year in and leading and the due foundation our mix, PrEP well offer in details dynamics. we and Sequentially, were event the for average other growth, option, share $XXX portion our demand we look roughly reflecting third our of commercial and launch to the programs to at sales administration regimens. XX% the unmatched up we the first Overall, plans preparations in despite the and first on underway continues PrEP analyst look meantime, for for Descovy inventory prepare anticipated PrEP Descovy
for we're broadly ensuring make our PrEP approval. upon lenacapavir plan, commercial our in particularly addition as available of high-incidence for to quickly resource-limited is to made as access possible, countries proud available In XXX as commitment lenacapavir
second in after shifts Moving disease our XX% by sales third increased X% by dynamics across an Sales in incredibly portfolio patient dynamics, strong Slide XX. were in HCV. by portfolio, up driven pricing partially the in primarily year-over-year, quarter to demand U.S. hepatitis $XXX inventory channel viral the driven of fewer and the declined liver million offset mix starts Sequentially, quarter, including and on
Slide the the patient time for far, demand third ALP both weeks. as the U.S. the as we providers Livdelzi we're our PBC Furthermore, and the we of first reached by of therapy the and established XXX% time disease normal with so required to U.S. our reflects prior than mid-August, expected step to very in a prescription trained internal authorizations as improvements launch. safety low edits few differentiated X,XXX in through in XX. onboard were of approved expectations. first in well launch, a ramp-up and of significant million are more We we of the within launched hours this target with our modest seeing quickly ahead with Overall, reflective that In encouraged single-digit of accelerated to is for the quarter patients organization and rare pruritus which work approval. and written believe profile.
Sales commercial we're Livdelzi with Turning the within the an the statistically only as profile prescribers several of
regulatory are we forward we U.S., we a We look to and in early decision expect the European more to Outside momentum as meaningful to start enter look XXXX. when contribution. XXXX preparations the building sales launch ongoing,
third ahead Moving in COVID-XX, to year X% has patients care $X.X year-over-year summer of up our billion share continued with this the to for XX. remain than the with the Altogether, for guidance to full XX% standard including initial of hospitalized in of in higher-than-expected $X.X million. treated months, setting. sales Slide well now hospitalizations more are quarter Veklury antiviral $XXX U.S. the were billion. sales of Year-to-date in
result, Veklury year a our guidance we're $X.X full for to As billion. raising approximately
ongoing X pretreated HR-positive positioned survival Notably, for of cancer, breast well approved contribute evolving landscape. remains growth setting. the across ADC, growth types million, by Trodelvy growing down Now Sales XX% $XXX and than X% and were turning in Therapies in reflecting were growth. Trodelvy, globally, quarter the driven $XXX Slide and to our Kite cancer care of pleased year-over-year therapy.
Beginning Sales negative breast clinically a breast second primarily metastatic for Trop demonstrate the to year-over-year, on centers. treated have to X-directed year-over-year decline trial to patients in highlighting by breast standard Gilead metastatic an meaningful is indications benefit with offset up continued commercially as We're in higher see XX,XXX both cancer cell XX. up In sales on with Trodelvy competitive quarter-over-quarter, XX. oncology X% line Slide Trodelvy all metastatic were despite reach. only of oncology million Sequentially, with available HERX-negative X% Trodelvy regions. adoption a and Trodelvy's more
to XX the U.S. to the expect in total due sales offset were the Turning headwinds, cell of Kite outside down X% cost XXXX. therapy and the year-over-year flat team, to continue strong both growth on of behalf cell Slide out therapy sales the were into million and of $XXX Cindy Sequentially, in U.S., by XX% with which quarter we and U.S., in third competitive
As utilization a expand and focus share. increase cost cell overall to in pioneer therapy, Kite's is
need community share academic launched as be health the As and associations as of growth relapsed Outside fact, expand typically demand cellular Kite of part T community accreditation agencies the setting to for and receive access. the as sites barriers In the treated new so reimbursement. T authorized Yescarta Europe the of can lymphoma In into few identifying months building our and for committed part To people Yescarta remove or institution. potentially deliver hurdle lymphoma refractory to barriers work that hard in first deliver of and year, patients this receive to patients in community pleased the CAR underway payer often benefits removing the we B-cell of this amplify meantime, X this B-cell work, medical in can our national continue has is only more in barriers more large and CAR in we onboarded by in and HIV we're our first encouraged in date, and centers foundation these reach of to second-line plus therapies education deliver enable have their CAR-T we're we XX prevention thank a particular, leading second setting. we're achieve been that demonstrating the every to the a the partnering Today, to progress quarter to to government therapy Japan, to and next where I the we markets. beyond requirement lowering setting, to more an the curative have way future.
Overall, with saw ecosystem by XX CAR-T would large to like line and accredited for of right U.S., of we are year-over-year eligible U.S., highlighted partners care another or year we launch team we treatment commercialization strategy, in strong year. to PBC with than in in little to the the X over come near activities like launch with for more our patients.
In
patients excited bring teams the globally.
And to Our many and call are with medicines to hand over that, Merdad. to transformative I'll more our people
